Gilead GS-US-540-5823: A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Remdesivir (GS-5734?) in Participants from Birth to < 18 Years of Age with COVID-19

Project: Research project

Project Details

StatusActive
Effective start/end date7/15/20 → 8/31/50

Funding

  • Gilead Sciences, Inc